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Abstract
Background: The SAVVY project aims to improve the analyses of adverse event (AE)
data in clinical trials through the use of survival techniques appropriately dealing with
varying follow-up times and competing events. Although statistical methodologies have
advanced, in AE analyses often the incidence proportion, the incidence density, or a non-
parametric Kaplan-Meier estimator are used, which either ignore censoring or competing
events. In an empirical study including randomized clinical trials from several sponsor
organisations, these potential sources of bias are investigated. The main purpose of the
empirical study is to compare the estimators that are typically used in AE analysis to the
non-parametric Aalen-Johansen estimator as the gold-standard. The present paper reports
on one-sample findings, while a companion paper considers consequences when comparing
safety between treatment groups.
Methods: Estimators are compared with descriptive statistics, graphical displays and
with a more formal assessment using a random effects meta-analysis. The influence of
different factors on the size of the bias is investigated in a meta-regression. Comparisons
are conducted at the maximum follow-up time and at earlier evaluation time points. Com-
peting events definition does not only include death before AE but also end of follow-up
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for AEs due to events possibly related to the disease course or safety of the treatment.
Results: Ten sponsor organisations provided 17 clinical trials including 186 types of inves-
tigated AEs. The one minus Kaplan-Meier estimator was on average about 1.2-fold larger
than the Aalen-Johansen estimator and the probability transform of the incidence density
ignoring competing events overestimated the AE probability even more. Leading forces
influencing bias were the amount of censoring and of competing events. The presence of
many competing events in our study decreased the amount of censoring. As a consequence,
the average bias using the incidence proportion was less than 5%. Assuming constant haz-
ards using incidence densities was hardly an issue provided that competing events were
accounted for.
Conclusions: Both the choice of the estimator of the cumulative AE probability and a
careful definition of competing events are crucial. There is an urgent need to improve
the guidelines of reporting risks of AEs so that the Kaplan-Meier estimator and the inci-
dence proportion are finally replaced by the Aalen-Johansen estimator with an appropriate
definition of competing events.
Keywords: Aalen-Johansen estimator, adverse events, competing events, drug safety,
incidence proportion, incidence density, Kaplan-Meier estimator
1 Background
Time-to-event or survival endpoints are common in clinical research [1, 2]. The obser-
vation of the event times is typically incomplete as a consequence of censoring, and the
statistical analysis, therefore, requires specialized techniques. This requirement holds for
both the evaluation of efficacy and safety. An important aim of the latter is the estima-
tion of the probability of an adverse event (AE) of a specific type within a specific time
interval, which, in a time-to-first-event analysis, is often done by the incidence proportion,
i.e., the number of patients with an observed AE (of a certain type) in a specific time
period divided by group size, or the (exposure adjusted) incidence density, which divides
by cumulative patient-time at risk. The worry is that the incidence proportion underesti-
mates the cumulative AE probability because it does not account for censoring [3, 4, 5, 6].
One minus a Kaplan-Meier estimator counting AEs as the event would account for cen-
soring, but not for competing events (CEs) such as death without prior AE. When CEs
are present, Kaplan-Meier is commonly used [7, 8] but bound to overestimate the cumula-
tive AE probability as the methodology implicitly assumes that every patient experiences
the AE under consideration, possibly after a CE such as death. The incidence density
also accounts for censoring but does not estimate a probability. Rather, it estimates the
AE hazard assuming it to be time-constant. However, this assumption is not realistic for
many drug-related adverse events[9, 10]. The interpretation of the incidence density as an
estimator of a hazard is challenging, but the incidence density may be transformed onto
the probability scale; typically, such transformations do not consider CEs [11], although
extensions are available [12].
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The concerns above are qualitative. However, the amount of bias, comparing, e.g., the
incidence proportion or one minus Kaplan-Meier with the non-parametric gold standard,
the Aalen-Johansen estimator [4] accounting for both CEs and censoring will depend on
the specific trial setting. In particular, the relative frequencies of observed AEs, observed
CEs and observed censorings add up to 100% at any point in time. The latter two are
leading forces influencing bias, and, e.g., the presence of many CEs in a time-to-first-event
analysis will impact the amount of censoring.
The SAVVY project group (Survival analysis for AdVerse events with Varying follow-
up times) is a collaborative effort from academia and pharmaceutical industry with the aim
to improve the analyses of AE data in clinical trials through the use of survival techniques
that account for varying follow-up times, censoring and CEs. Here, we report one-sample
results from an empirical study of an opportunistic sample of randomized clinical trials
from several sponsor companies. The aim is to illustrate possible biases when quantifying
absolute AE risk in single samples including categorization into AE frequency categories.
Results when comparing safety between treatment groups in the two-sample case are in
a companion paper[13]. Individual trial data analyses were run within the sponsor or-
ganisations using SAS and R software provided by the academic project group members.
Only aggregated data necessary for meta-analyses were shared and meta-analyses were run
centrally at the academic institutions.
2 Methods
A detailed Statistical Analysis Plan is available elsewhere [14]. Here, we briefly summarize
one-sample estimators and methods of meta-analysis. Properties and estimands of the
estimators are discussed elsewhere[14, 6]. We describe in more detail the definition of CEs
which has an immediate consequence on the estimation procedures.
2.1 One-sample estimators
We will consider the following estimators of the cumulative AE probability or ‘AE risk’ in
a time-to-first-event analysis. Since both probabilities and the amount of censoring [15]
are time-dependent, we will allow for different evaluation times called τ . These evaluation
times either imposed no restriction, i.e., evaluated the estimators until the maximum follow-
up time, or considered the minimum of quantiles of observed times in the two treatment
groups; the quantiles were 100%, 90%, 60% and 30%. We will report results from ‘Arm
E’, denoting the experimental treatment groups. The incidence proportion is
IPE(τ) =
no. of patients w. observed AE on [0, τ ] in E
nE
, (1)
where nE denotes sample size in group E. This estimator will be called incidence proportion
in the following.
The AE incidence density is
IDE(τ) =
no. of patients w. observed AE on [0, τ ] in E
patient-time at risk in E restricted by τ
(2)
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which we transform onto the probability scale using
1− exp (−IDE(τ) · τ) , (3)
called probability transform incidence density ignoring CE in the following. The one minus
Kaplan-Meier estimator only codes observed AEs as an event and censors anything else
on [0, τ ].
An incidence densities analysis accounting for CEs uses the competing incidence density
IDE(τ) =
no. of patients w. observed CE on [0, τ ] in E
patient-time at risk in E restricted by τ
(4)
such that we get the following AE-probability estimator
IDE(τ)
IDE(τ) + IDE(τ)
(
1− exp(−τ · [IDE(τ) + IDE(τ)])
)
, (5)
called probability transform incidence density accounting for CE in the following. Finally,
the Aalen-Johansen estimator generalizes (5) to a fully non-parametric procedure and
decomposes the usual one minus Kaplan-Meier estimator of the time-to-any-first-event
(AE or competing) into estimators of the cumulative AE probability plus the cumulative
CE probability [4].
2.2 Definition of competing events
The definition of events as ‘competing’ is essential to both the Aalen-Johansen estimator
and the competing incidence density. CEs (or ‘competing risks’) are events that preclude
the occurrence or recording of the AE under consideration in a time-to-first-event analysis.
One important competing event is death before AE. In addition, any event that would both
be viewed from a patient perspective as an event of his/her course of disease or treatment
and would stop the recording of the interesting AE will be viewed as a CE. To illustrate,
premature discontinuation of study treatment which leads to end of AE recording will
be handled as a CE[16]. Consequently, possibly disease- or safety-related loss to follow-
up, withdrawal of consent and discontinuation is handled as a competing event as this is
typically related to an event associated with the disease course or therapy.
In order to investigate the impact of the definition of CEs, we also investigated a ‘death
only’ scenario, which only treated death before AE as competing, but not the other CEs.
This estimator will be called Aalen-Johansen (death only) in the following.
The data generation mechanism underlying the clinical trials is based on the hazard
of the AE, the hazard of the CE, and the distribution of the censoring times, where the
hazards are not restricted to be constant[14]. But not all estimators suggested for analysing
AEs can adequately deal with all three processes. Table 1 gives an overview whether the
estimators account for the three sources of bias, i.e., censoring, no constant hazards, and
CEs. The incidence proportion ignores CEs and censoring in the analysis in the same way
as the respective patients are counted in the denominator as if they had been followed for
the entire study period. This is a proper handling of the CEs as it correctly takes into
account that an AE cannot occur after the patient had experienced a CE. It is an improper
handling of censoring as it incorrectly implies that an AE could have been observed over
the entire follow-up period, which is not true due to censoring.
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Table 1: Overview whether the estimators deal with the possible sources of bias.
Accounts for Makes no constant Accounts for
censoring hazard assumption CEs
Incidence proportion No Yes Yes
Probability transform incidence density Yes No (AE Hazard) No
ignoring CEs
1-Kaplan-Meier Yes Yes No
Probability transform incidence density Yes No (AE and CE Hazard) Yes
accounting for CEs
death only Aalen-Johansen estimator Yes Yes Yes (Death only)
gold-standard Aalen-Johansen estimator Yes Yes Yes
The Aalen-Johansen estimator is the only estimator that is able to deal with all three
potential sources of bias and is therefore considered the gold standard estimator and will
serve as a benchmark for comparison of results. In the following, we will use the term bias
for deviations of the estimators from this benchmark estimator and not for the difference
to the true value. This is considered appropriate as the differences of the estimators to the
Aalen-Johansen estimator converge in probability to the asymptotic bias.
2.3 AE frequency categories
According to the European Commission’s guideline on summary of product characteristics
(SmPC)[17] and based on the recommendations of the CIOMS Working Groups III and
V[18] the frequency categories of AE risk in the most representative exposure period are
respectively classified as ‘very rare’, ‘rare’, ‘uncommon’, ‘common’ and ‘very common’
when found to be < 0.01%, < 0.1%, < 1%, < 10%, ≥ 10%. Frequency categories obtained
with the different estimators will be compared to frequency categories obtained with the
gold-standard Aalen-Johansen estimator.
2.4 Random effects meta-analysis and meta-regression
In the meta-analysis and meta-regression, the ratios of the AE probability estimates ob-
tained with the different estimators divided by the AE probability obtained with the gold-
standard Aalen-Johansen estimator are considered on the log-scale. The standard errors
of these log-ratios are calculated with a bootstrap to account for within trial dependencies.
Then, a normal-normal hierarchical model is fitted and the exponential of the resulting
estimate can be interpreted as the average ratio of the two estimators.
In a meta-regression it is further investigated which variables impact this average ratio.
Therefore, the proportion of censoring, the evaluation time point τ , i.e., the maximal time
to event in years (AE, CE or censoring) observed under the given evaluation time, and the
size of the AE probability estimated by the gold-standard Aalen-Johansen are included as
covariates in a univariable and a multivariable meta-regression. The covariates are centered
in the meta-regression.
5
0.00
0.25
0.50
0.75
1.00
observed AE observed death
 before AE
observed other
 competing event
observed censoring
re
la
tiv
e
 fr
eq
ue
nc
ie
s
Figure 1: Relative frequencies of observed events
3 Results
3.1 Description of the data
Ten organisations provided 17 trials including 186 types of AEs (median 8; interquartile
range [3, 9]). Twelve (71.6% out of 17) trials were from oncology, nine (52.9%) were actively
controlled and eight (47.1%) were placebo controlled. The trials included between 200
and 7171 patients (median: 443; interquartile range [411, 1134]). For the comparison of
the AE probabilities we focus on the experimental treatment group. The corresponding
results of the control group are displayed in the companion paper[13]. Median follow-up
of the treatment group was 927 days (interquartile range [449, 1380]). In the experimental
treatment group, the median of the calculated gold-standard Aalen-Johansen estimators
was 0.092 (minimum 0 and maximum 0.961).
Figure 1 displays for the 186 types of AEs boxplots of the observed relative frequencies,
i.e., the number of patients with a specific type of event divided by the total number of
patients, namely of ‘observed AE’, ‘observed death before AE’, ‘observed other competing
events’, and ‘observed censoring’ for the maximal follow-up time.
The figure illustrates a smaller amount of observed censoring compared to observed
other, i.e., non-death CEs. That is, AE recording often ended due to death or other CEs
such as treatment discontinuation preventing censoring of the time to AE. There are also
much less death events than other CEs.
3.2 Comparison of AE probability estimators
Panel A of Figure 2 shows box plots of the ratio of the one-sample estimators defined
earlier divided by the gold-standard Aalen-Johansen estimator for the maximum follow-
up time and one earlier evaluation time chosen as to the 90% quantile. As the incidence
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proportion implicitly accounts for CEs (but not for censoring) as explained above, the small
amount of censoring which is a consequence of the high amount of other CEs explains why
the incidence proportion and the Aalen-Johansen estimator are of similar size in many
situations. But it has to be emphasized that in extreme cases an underestimation of up to
seventy percent was present.
Both one minus Kaplan-Meier and the probability transform incidence density ignoring
CE overestimate the AE probability, and this is also true for the Aalen-Johansen estimator
that only considers death before AE as competing. Interestingly, the probability transform
incidence density ignoring CE appears to be worst, while the probability transform inci-
dence density accounting for CE performs much better than the other three procedures
which are clearly biased resulting in extreme overestimation in many situations, up to a
factor of five. These biases become less pronounced when looking at earlier evaluation
times which prevent CEs and censoring after the respective end of evaluation time to enter
calculations.
3.3 Impact on frequency categories
The impact on frequency categories is illustrated in Table 2, where we have exemplarily
chosen the maximum follow-up time as most representative exposure period. Some switches
to neighboring categories are detected. The probability transform of the incidence density
ignoring CEs derives a higher AE frequency category for 38 types of AEs, and the one
minus Kaplan-Meier estimator for 16 types of AEs. The probability transform of the
incidence density accounting for CE obtains a higher category for nine types of AEs but
also a lower category for one type of AE. Here, the definition of the competing event
is again of importance. The death only Aalen-Johansen estimator categorizes 14 types of
AEs to a higher category than the gold-standard Aalen-Johansen estimator. The incidence
proportion derives only two times a different AE frequency category than the gold-standard
Aalen-Johansen estimator. The good performance of the incidence proportion is closely
connected to the CE definition, i.e. the maturity of data at the time of the analysis. If in
the comparison to the incidence proportion the Aalen-Johansen (death only) is used instead
of the gold-standard, the category common instead of very common is obtained for 15 types
of AEs and one type of AE is categorized to uncommon using the incidence proportion
but to common using the Aalen-Johansen that only considers death as a competing event
estimator (see last five rows of Table 2).
3.4 Random effects meta-analysis
In a meta-analysis of the log-ratio of the incidence proportion divided by the Aalen-
Johansen estimator evaluated at the maximum follow-up time, the average ratio was found
to be 0.972 with a 95%-confidence interval of [0.965, 0.980]. The respective result for the
probability transform incidence density ignoring CE was 2.097 [1.994, 2.205] and for one
minus Kaplan-Meier was 1.214 [1.184, 1.245]. Accounting for competing risks in an inci-
dence densities-analysis (probability transform incidence density accounting for CE) gave
a result of 1.130 [1.112, 1.150], while the Aalen-Johansen (death only) estimator lead to an
average of 1.170 [1.145, 1.195]. These results confirm the visual impression gathered from
the boxplots in Panel A of Figure 2, but we note that Panel A of Figure 2 also displays
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Figure 2: Panel A: Accepting the all event definition of competing events as gold-standard,
the ratios of one-sample estimator divided by gold-standard Aalen-Johansen estimator
are displayed. Two different evaluation times are displayed. The left boxplots are the
results for the estimators being evaluated at the 90% quantile and the right boxplots are
the results of the evaluation time with no restriction, i.e., at the end of follow-up. The
following abbreviations are used for the estimators: incidence proportion (IP), probability
transform of the incidence density ignoring CE (prob trans incid dens ignoring CE), one
minus Kaplan-Meier (1-KM), probability transform of the incidence density accounting for
CE (prob trans incid dens acc for CE), death only Aalen-Johansen estimator (AJE death
only). Panel B: Plots of the kernel density estimates of the ratios of the AE probability of
the estimators divided by the gold-standard Aalen-Johansen estimator.
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Table 2: The impact of the choice of one-sample estimator on AE frequency categories
for the maximal follow-up time. Deviations from the Aalen-Johansen estimator are the
non-diagonal entries. The first rows consider the gold-standard Aalen-Johansen estimator
and the last five rows the comparison of the incidence proportion and the Aalen-Johansen
(death only) estimator. Diagonal entries are set in bold face. Non-diagonal zeros are
omitted from the display.
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biases in individual trials which are much larger than the meta-analytical averages.
3.5 Random effects meta-regression
The influence of different factors on the size of the bias was investigated in univariable and
multivariable meta-regression. The percentage of censoring, the size of the AE probability
estimated by the gold-standard Aalen-Johansen, and the evaluation time point were con-
sidered and included as covariates in the meta-regression models. In Tables 3 results are
exemplarily displayed when evaluating estimators using the maximum follow-up time as
evaluation time.
Covariates were centered, i.e., the row ‘average risk ratio’ contains the average ratio of
the estimator of interest and the Aalen-Johansen estimator if the covariate takes its mean.
Those means were 31.5% censoring, 52.6% competing events, 971 days maximum follow-up
time, and a size of the AE probability estimated by the Aalen-Johansen estimator of 0.165.
For example, for the comparison of the incidence proportion and the Aalen-Johansen esti-
mator the estimated average ratio of the two estimators in a trial with 31.5% censoring is
0.974. Furthermore, in a trial with 10% more censoring the estimated average ratio is in-
creased by the factor 0.999 but the unit value is contained in the corresponding confidence
interval. So, the amount of underestimation by the incidence proportion which does not
account for censoring slightly increases with an increasing amount of censoring. Consider-
ing the estimators that either do not (probability transform incidence density ignoring CE,
one minus Kaplan-Meier) or only partially (Aalen-Johansen (death only)) account for CE,
one finds that both a higher amount of censoring and a higher AE probability decrease the
amount of overestimation. The explanation goes hand in hand with the increased average
ratios for higher amounts of CEs as these estimators do account for censoring, and in-
creased censoring will, in general, lead to a smaller amount of observed competing events.
Likewise, a higher AE probability will, in general, lead to a smaller probability of CEs.
These results are confirmed by the multivariable meta-regression.The amount of CEs
is not included in the multivariable meta-regression as there is a strong dependence with
the amount of censoring and the size of the AE probability estimated by the gold-standard
Aalen-Johansen estimator.
3.6 Variability
Even though on average the incidence proportion does well in this sample of selected AEs
the possible variability must not be neglected.
Considering the plots of the kernel density estimates of the ratios of the different esti-
mators of the AE probability in Panel B of Figure 2, the ratio of incidence proportion and
the gold standard is most often close to one. But there are also peaks of the estimated
kernel density at smaller ratios indicating that the estimators are not always compara-
ble. For the ratio of the probability transform of the incidence density accounting for CEs
and the gold standard most values are slightly larger than one at the maximum follow-up
time. At the earlier follow-up time according to the 90% quantile the peak is closer to
one with less variability present. The ratios of the one minus Kaplan-Meier and death
only Aalen-Johansen estimator to the gold standard have few values close to one. For the
majority of AE types these two estimators largely overestimate the AE probability. Both
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Table 3: Univariable and multivariable meta-regression. Average risk ratio and multiplicative change by 10% increase in censoring,
10% increase in CEs, one additional year of observation or a 0.1 greater AE probabiltiy. Thereby, the size of the AE probability is
estimated by the gold-standard Aalen-Johansen estimator.
probability transform probability transform
incidence incidence density 1-Kaplan-Meier incidence density Aalen-Johansen
proportion ignoring CE accounting for CE death only
Univariable meta-regression
% censoring average risk ratio 0.974 [0.964; 0.983] 2.308 [2.217; 2.403] 1.257 [1.226; 1.288] 1.101 [1.086; 1.116] 1.201 [1.175; 1.228]
10% increase 0.999 [0.996; 1.002] 0.916 [0.903; 0.929] 0.973 [0.965; 0.980] 1.026 [1.021; 1.031] 0.979 [0.972; 0.986]
%CEs average risk ratio 0.976 [0.969; 0.984] 2.191 [2.141; 2.243] 1.240 [1.214; 1.267] 1.124 [1.109; 1.140] 1.190 [1.168; 1.213]
10% increase 1.003 [1.000; 1.006] 1.127 [1.117; 1.138] 1.036 [1.028; 1.045] 0.977 [0.971; 0.982] 1.029 [1.021; 1.036]
size of AE average risk ratio 0.973 [0.966; 0.980] 2.105 [2.005; 2.210] 1.215 [1.185; 1.246] 1.131 [1.112; 1.150] 1.171 [1.146; 1.197]
probability increase of 0.1 0.996 [0.992; 1.000] 0.954 [0.930; 0.980] 0.995 [0.982; 1.008] 0.993 [0.984; 1.003] 0.993 [0.982; 1.004]
evaluation average risk ratio 0.972 [0.964; 0.980] 2.094 [1.994; 2.199] 1.214 [1.184; 1.244] 1.131 [1.112; 1.150] 1.170 [1.145; 1.195]
time one additional year 0.993 [0.987; 1.000] 1.054 [1.021; 1.087] 1.015 [0.999; 1.033] 0.996 [0.986; 1.007] 1.013 [0.998; 1.027]
Multivariable meta-regression
average risk ratio 0.976 [0.966; 0.985] 2.407 [2.348; 2.468] 1.277 [1.246; 1.308] 1.097 [1.082; 1.113] 1.218 [1.192; 1.245]
%censoring 10% increase 0.997 [0.994; 1.000] 0.890 [0.882; 0.899] 0.965 [0.957; 0.973] 1.028 [1.023; 1.034] 0.972 [0.965; 0.979]
size of AE probability increase of 0.1 0.995 [0.991; 0.999] 0.893 [0.882; 0.904] 0.972 [0.961; 0.983] 1.008 [1.000; 1.016] 0.975 [0.965; 0.985]
evaluation time one additional year 0.994 [0.988; 1.000] 1.036 [1.021; 1.051] 1.014 [1.000; 1.027] 1.003 [0.995; 1.011] 1.011 [0.999; 1.024]
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plots illustrate pronounced variability for probability transform of the incidence density
ignoring CE.
3.7 Exemplary results from single trials
A closer look is taken at single AE types in trials for which extreme under- or overestimation
is present, i.e. extreme values in the right panel boxplots in Figure 2. For example, the
largest underestimation of the incidence proportion is for an AE which is only observed for
three out of 274 patients. This corresponds to an incidence proportion of 0.011. However,
an Aalen-Johansen estimate of 0.037 is obtained. This corresponds to a ratio of 0.294 with
a 95% confidence interval of [0.084; 1.025], where the confidence interval has been obtained
using the bootstrap. As 27.0% of the observations for this type of AE are censored, the
amount of censoring is below the mean censoring rate of all types of AEs. Moreover, for
this type of AE 17 deaths (6.2%) and 180 other CEs (65.7%) are observed. This type of AE
does not only contribute the largest underestimation of the incidence proportion but also
of the probability density of the incidence density accounting for CEs for which an estimate
of 0.012 is obtained (ratio of 0.329 with 95% CI [0.094; 1.148]). Furthermore, for this type
of AE the largest overestimation of the one minus Kaplan-Meier estimator (estimate of
0.208 and ratio of 5.575 [1.813; 17.147]) and the Aalen-Johansen (death only) estimator
(estimate of 0.190 and ratio of 5.090 [1.815; 14.276]) is calculated. These impressive ratios
are partly due to the small value of the gold-standard Aalen-Johansen estimate, but we
stress that also the difference between one minus Kaplan-Meier and the gold standard is
quite pronounced (0.208 vs. 0.037).
In another extreme example with a higher AE probability the obtained incidence pro-
portion is 0.059 and the Aalen-Johansen estimate is 0.109 (ratio 0.534 [0.529; 0.540]). For
this type of AE many censored observations are present (63.3% of 752 patients). Moreover,
44 AEs are observed, 137 deaths (18.2%), and 95 other CEs (12.6%). Here, due to the high
amount of censoring one can expect in advance the incidence proportion not doing well.
3.8 Role of Censoring
To explicitly investigate the role of censoring without the methodological complication of
CEs the composite endpoint combining AEs and CEs is considered, which results in a
single endpoint survival setting. As a consequence the gold standard in this setting is
the one minus Kaplan-Meier estimator which is compared to the incidence proportion (see
Figure 3).
In the composite endpoint analysis the underestimation of the incidence proportion is
more pronounced than in the analyses of the AE probability presented above. One reason
is that even in the presence of censoring for the one minus Kaplan-Meier estimator the
type of the last event is most important. If the last event is an AE or CE the one minus
Kaplan-Meier estimator is equal to one, even though censoring has been observed at earlier
follow-up times. The incidence proportion is only equal to one if no censoring is observed.
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Figure 3: Ratios of incidence proportion of the composite endpoint combining AE and CE
divided by composite 1-Kaplan-Meier estimator
4 Conclusion
The starting point of the present investigation was that AE analyses in terms of AE
probabilities, an important aspect of drug safety evaluations, should account for the time
under observation and censoring if the latter is imposed by the data at hand. However,
while primary efficacy endpoints often are time-to-event composites such as progression-free
and overall survival which every patient experiences, although possibly after study closure,
the occurrence of AE (of a certain type) usually is subject to CEs such as death before AE.
Survival analyses accounting for CEs is methodologically well established, but practical use
lacks behind [7, 19]. Failure to account for censoring (e.g., incidence proportion) or CEs
(e.g., one minus Kaplan-Meier) will generally lead to biased quantification of absolute AE
risk, but the amount of bias has been unclear.
In this study, we confirmed that one minus Kaplan-Meier should not be used to estimate
the cumulative AE probability, as it is bound to overestimate as a consequence of ignoring
CEs. Interestingly, we found that the incidence proportion performed surprisingly well
when compared to the gold-standard Aalen-Johansen estimator. One reason may be a high
amount of CEs before possible censoring. But not only the proportion of censoring but also
the timing of the censoring are relevant as the first example of the single trials described in
detail showed. This example led to the largest bias although the proportion of censoring
was below average. The observed proportion and timing of censoring in this project are
a consequence of twelve out of 17 trials being from oncology in which compared to other
therapeutic areas AEs and CEs are often observed early during follow-up and censoring
occurs much later. We also note that the observed constellation of CEs and censoring
results from a sample of completed trials after the final analysis had been performed. The
proportion of censoring may be different at the time point of a safety interim analysis of
trials which are typically presented to data safety monitoring boards. For this situation
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the different estimators may behave differently [20].
This finding must not be interpreted as a carte blanche to use AE incidence proportions
based on censored data. In fact, comparable performance of incidence proportion and
Aalen-Johansen did not only rely on a high amount of CEs, but in particular on a careful
definition of what kind of events constitute a competing event as outlined earlier. In other
words, use of the incidence proportion implicitly assumes events to be competing as defined
in the methods section. This aspect is somewhat subtle, but nicely highlighted by the fact
that an analysis accounting for both censoring and only death as CEs (Aalen-Johansen
(death only)) also led to overestimating AE risk, although the bias was not as pronounced
as for one minus Kaplan-Meier.
We also found that previous worries about the constant hazard assumption underly-
ing incidence densities were justified in that a simple transformation of the AE incidence
density onto probabilities (probability transform incidence density ignoring CE) performed
worst. However, accounting for competing events in an analysis that parametrically mim-
icked the non-parametric Aalen-Johansen performed better than both one minus Kaplan-
Meier and Aalen-Johansen (death only); in this sense, ignoring CEs appeared to be worse
than assuming constant hazards in our empirical study.
Most of the results were shown for the situation where the maximum follow-up time were
chosen as evaluation time. When looking at earlier evaluation times defined by quantiles
of the observed times, the resulting bias was, in general, less pronounced, due to a reduced
relative frequency of competing events and of censoring (see figure 1). We regarded the
situation of including all data up to the maximum follow-up time as the most relevant as
this is the usual practice.
Our empirical study does have shortcomings. Using an opportunistic sample of ran-
domized clinical trials from several sponsor companies, we have been able to illustrate
possible consequences when quantifying AE risk in a manner that ignores censoring or
CEs. However, being opportunistic, the sample does not lend itself to straightforward
generalizations. More than two thirds of the trials were from oncology. These came with
a high amount of CEs, which, in turn, led to comparable performances of incidence pro-
portion and Aalen-Johansen. The vast majority of AEs were classified as ‘common’ or
‘very common’, and AEs were also heterogeneous, coming from different therapeutic areas
and were not necessarily treatment-related. These shortcomings were to be anticipated
from an opportunistic sample, but it was our aim in this ‘real-world’ setting to investigate
and demonstrate which biases can occur in practice. These shortcomings do also impact
the comparison of adverse event risks between treatment groups[13]. The observed results
motivate future empirical investigations on how to quantify AE risk with the aim of better
generalizability. As a further point, it was not the aim of this investigation to accurately
estimate AE probabilities, but to compare different estimators. Our present study does not
allow for a meaningful comparison of results in different diseases. Follow-up investigations
concentrating on trials in specific disease areas are planned.
A methodological restriction is that we have focused our investigation on an analysis
which mostly does not consider AEs after treatment discontinuation due to e.g. disease
progression in oncology. This restriction is, in particular, due to trial design when treat-
ment discontinuation leads to stopping AE recording after a pre-specified time period. In
addition, in oncology, it is not uncommon that patients enter a different clinical trial after
progression which further complicates matters. Another methodological restriction is that
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we did not consider recurrent AEs, but only first events. It is desirable to consider more
complex event histories, also beyond time-to-first-event. However, any such consideration
will need to account for CEs (and censoring), and our investigation therefore also informs
methodological considerations for analysing such more complex event histories. In other
words, both AEs after treatment discontinuation and recurrent AEs will still be subject to
competing events.
Our recommendation is to ‘play it safe’ when analysing AE risk in a time-to-first-
event analysis and neither hope for a small amount nor a large amount of CEs nor a
favorable interplay of the distributions of the times of AEs, CEs, and censorings. In the
former case, one minus Kaplan-Meier might work well, while in the latter two cases the
incidence proportion might do so. Playing it safe, we recommend using the Aalen-Johansen
estimator which equals one minus Kaplan-Meier in the absence of CEs and equals the
incidence proportion in the absence of censoring and does low for presence of both CEs and
censoring. Guidelines for reporting AEs should, therefore, advocate the Aalen-Johansen
estimator instead of incidence proportion, incidence density and one minus Kaplan-Meier.
Data and code
Individual trial data analyses were run within the sponsor organizations using SAS and R
software provided by the academic project group members. Only aggregated data neces-
sary for meta-analyses were shared and meta-analyses were run centrally at the academic
institutions.
A markdown file providing exemplary code to compute all the estimators discussed in
this paper for a given dataset is available on github: https://github.com/numbersman77/AEprobs.
The corresponding output is available as html file: https://numbersman77.github.io/AEprobs/SAVVY_AEprobs.html.
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